https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Earns-15-Million-Milestone-from-Astellas-upon-Initiation-of-Enrollment-in-Linaclotide-Phase-III-IBS-C-Clinical-Trial-in-Japan/default.aspx
Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients.
- November 20, 2014